Interim report 2026
Filed with HKEX · Stock code 6955 · · 51 pages · English
2 Company Overview 3 Corporate Information 5 Financial Highlights 6 Management Discussion and Analysis 29 Other Information 35 Independent Review Report 36 Interim Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income 37 Interim Condensed Consolidated Statement of Financial Position 38 Interim Condensed Consolidated Statement of Changes in Equity 39 Interim Condensed Co
Shandong Boan Biotechnology Company., Limited on 6ix
Earlier from Shandong Boan Biotechnology
- Next Day Disclosure Return
- Voluntary announcement cde approval of IND application for BA1203 (a masked anti-PD-1/IL-2 fusion protein)
- Poll results of the annual general meeting held on 22 June 2026
- Voluntary announcement licensing of dulaglutide injection in the U.S.
Later from Shandong Boan Biotechnology
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
- Continuing connected transactions promotion cooperation agreement
- Voluntary announcement first subject enrolled in phase i clinical trial of BA1203 (a masked anti-PD-1/IL-2 fusion protein) in China
- Voluntary announcement the company enters into licensing agreement for denosumab injection 60 mg in japan
Follow Shandong Boan Biotechnology into a list and get an email when it puts out news.
Follow Shandong Boan Biotechnology